Bi Hong-sheng, Cui Yan, Zhang Jian-hua, Wang Xing-rong, Xie Xiao-feng
Jinan Shierming Eye Hospital, Jinan 250002, China.
Zhonghua Yan Ke Za Zhi. 2006 Jan;42(1):37-41.
To evaluate the efficacy of 5-fluorouracil polyactic acid microsphere in prevention of proliferative vitreoretinopathy (PVR).
5-fluorouracil polyactic acid microsphere or 5-fluorouracil were used to implant into rabbits vitreous cavity. 48 healthy rabbits were divided into 3 groups: rabbits in Group 1 received implantation of 5-fluorouracil polyactic acid microsphere; rabbits Group 2 served as polyactic acid microsphere control; rabbits in Group 3 received only 5-fluorouracil powder. Macrophages were injected into vitreous cavity of rabbit to induce PVR. 0.2 ml BSS containing 25 mg microsphere with 2.6 mg 5-fluorouracil was injected into vitreous cavity of two eyes in Group 1. 0.2 ml BSS containing 25 mg microsphere without medicine and 0.2 ml BSS containing 2.6 mg 5-fluorouracil were injected into rabbits vitreous cavity in Group 2 and 3 respectively, Drug content in aqueous humor was measured regularly. Release feature of 5-fluorouracil polyactic acid microsphere in vivo was observed. The efficacy of the inhibition of PVR was evaluated according to Ryan's grade of proliferative vitreoretinopathy.
The releasing time of 5-fluorouracil polyactic acid microsphere was much longer than 5-fluorouracil powder. Its half life T(1/2) was 379.05 h with low clearance rate. The attack rate of retinal detachment in Group 2 was 62.5% and 71.9% on the 21st and 28th day respectively. The attack rate of retinal detachment in Group 3 was 64.3% and 78.6% whereas that of Group 1 was 13.3% and 13.3% on the 21st and 28th day. There was statistical difference in retinal detachment rate in Group 1 and 2 or 3 (P < 0.01). No differences was found in retinal detachment ration in Group 2 and 3 (P > 0.05).
Implantation of 5-fluorouracil polyactic acid microsphere into vitreous cavity can effectively prevent proliferative vitreoretinopathy induced by macrophages in rabbit model.
评估5-氟尿嘧啶聚乳酸微球预防增殖性玻璃体视网膜病变（PVR）的疗效。
将5-氟尿嘧啶聚乳酸微球或5-氟尿嘧啶植入兔玻璃体腔。48只健康兔分为3组：第1组兔接受5-氟尿嘧啶聚乳酸微球植入；第2组兔作为聚乳酸微球对照组；第3组兔仅接受5-氟尿嘧啶粉剂。向兔玻璃体腔注射巨噬细胞以诱导PVR。第1组两只眼的玻璃体腔分别注射含25mg微球及2.6mg 5-氟尿嘧啶的0.2ml平衡盐溶液（BSS）。第2组和第3组兔的玻璃体腔分别注射含25mg无药物微球的0.2ml BSS和含2.6mg 5-氟尿嘧啶的0.2ml BSS，定期测量房水中的药物含量。观察5-氟尿嘧啶聚乳酸微球在体内的释放特性。根据Ryan增殖性玻璃体视网膜病变分级评估抑制PVR的疗效。
5-氟尿嘧啶聚乳酸微球的释放时间远长于5-氟尿嘧啶粉剂。其半衰期T（1/2）为379.05小时，清除率低。第2组在第21天和第28天视网膜脱离的发生率分别为62.5%和71.9%。第3组在第21天和第28天视网膜脱离的发生率分别为64.3%和78.6%，而第1组在第21天和第28天为13.3%和13.3%。第1组与第2组或第3组的视网膜脱离率有统计学差异（P<0.01）。第2组和第3组的视网膜脱离率无差异（P>0.05）。
向玻璃体腔植入5-氟尿嘧啶聚乳酸微球可有效预防兔模型中由巨噬细胞诱导的增殖性玻璃体视网膜病变。
